BML-277 (CAS 516480-79-8)
See product citations (2)
QUICK LINKS
BML-277 is a compound recognized for its role as a checkpoint kinase 2 (Chk2) inhibitor. Chk2 is a key enzyme in the cellular DNA damage response mechanism and is activated by DNA strand breaks. By inhibiting Chk2, BML-277 is utilized in research to study the cellular responses to DNA damage, particularly in the context of cell cycle regulation and the maintenance of genomic stability. By modulating Chk2 activity, BML-277 helps to dissect the pathways that lead to cell cycle arrest, DNA repair, and apoptosis. This may be useful in oncological research, where understanding the regulation of the DNA damage response integral. The compound is also employed in studies focusing on DNA-damaging agents which prevent cancer cells from activating their repair mechanisms.
BML-277 (CAS 516480-79-8) References
- Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. | Arienti, KL., et al. 2005. J Med Chem. 48: 1873-85. PMID: 15771432
- Cell cycle kinase CHEK2 in macrophages alleviates the inflammatory response to Staphylococcus aureus-induced pneumonia. | Xie, F., et al. 2022. Exp Lung Res. 48: 53-60. PMID: 35075953
- CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. | Hsieh, CC., et al. 2022. Br J Cancer. 127: 1615-1628. PMID: 35999268
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BML-277, 10 mg | sc-200700 | 10 mg | $132.00 | |||
BML-277, 50 mg | sc-200700A | 50 mg | $492.00 |